Any current/future new fundraising through debt or equity?

There is no explicit mention of any new fundraising through debt or equity in the provided transcript. The company is undertaking significant capex of INR 1,500-1,800 crores in FY25 and expects similar or upward capex in FY26, primarily funded through ongoing resources. Chetan Gandhi mentioned that debt levels are not expected to reduce on an absolute basis due to ongoing capex, but working capital optimization efforts are underway. The management did not indicate any plans for new equity fundraising. Cost of debt is currently around 7.5%-8% and expected to remain similar next year, indicating

Any current/future capex/capital investment/strategic investment?

FY'24 capex was over INR 1,280 crore on project expansions. Planned capex for FY'25 is INR 1,500-1,800 crore. Major ongoing expansions include Acid Phase-2 Capacity Expansion, Specialty Chemicals Blocks, Ethylation, Nitro Toluene capacities, and asset upgradation. Phase-1 of the Chloro Toluene project is expected to commence by FY'26. FY'26 capex likely to exceed INR 1,000 crore but exact numbers are yet to be finalized. Over the next two years, total planned investment is approximately INR 3,000-3,500 crore. More than 50% of FY'26 capex will be allocated to the new site expansion at Jhagadia,

Future growth expectations in sales/revenue/volumes?

Volume growth for FY'25 is expected between 20% to 30%, with growth starting from Q1 and accelerating substantially in the second half (Q2 onwards). Expansion projects including Acid Phase-2, Ethylation, Nitro Toluene, and specialty chemical blocks are expected to be commissioned in FY'25, contributing to volume and revenue growth. Chloro Toluene and downstream product plants are planned to be commissioned by FY'26, adding higher-margin products and improving EBITDA margins. Long-term contracts, including MMA and Deepak Fertilizers contracts, are expected to ramp up, increasing contract revenu

Future growth expectations in earnings/operating earnings/profits/EPS?

EBITDA guidance for FY25 is maintained at Rs. 1,450-1,700 crore, supported by volume ramp-ups and operating leverage. Volume growth expected to start from Q1 FY25, with stronger growth from Q2 onwards due to new project commencements. Margins expected to improve structurally from FY26-27 with increased sales of value-added Chloro Toluene products. Existing asset expansions could add another 10-15% EBITDA (~Rs. 2,000 crore potential). Domestic demand in agrochemical expected to recover strongly in the second half of FY25. Capex of Rs. 1,500-1,800 crore planned for FY25 focusing on capacity expa

IN US

Sale is live|00:00:00left today

Aarti Industries LtdQ1 FY24Chemicals & Petrochemicals

Aarti Industries Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹457P/E: 41.0Market Cap: ₹16.9K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Volume growth for FY'25 is expected between 20% to 30%, with growth starting from Q1 and accelerating substantially in the second half (Q2 onwards).
→Expansion projects including Acid Phase-2, Ethylation, Nitro Toluene, and specialty chemical blocks are expected to be commissioned in FY'25, contributing to volume and revenue growth.
→Chloro Toluene and downstream product plants are planned to be commissioned by FY'26, adding higher-margin products and improving EBITDA margins.
→Long-term contracts, including MMA and Deepak Fertilizers contracts, are expected to ramp up, increasing contract revenues significantly in FY'25 and beyond.
→Agrochemical demand is expected to remain muted in the first half of calendar year 2024 and improve towards FY'25.
→Overall, gradual recovery in discretionary and non-discretionary segments will support sustained sales and volume growth over the next 2-3 years.

Margin guidance

Category 3

→EBITDA guidance for FY25 is maintained at Rs. 1,450-1,700 crore, supported by volume ramp-ups and operating leverage.
→Volume growth expected to start from Q1 FY25, with stronger growth from Q2 onwards due to new project commencements.
→Margins expected to improve structurally from FY26-27 with increased sales of value-added Chloro Toluene products.
→Existing asset expansions could add another 10-15% EBITDA (~Rs. 2,000 crore potential).
→Domestic demand in agrochemical expected to recover strongly in the second half of FY25.
→Capex of Rs. 1,500-1,800 crore planned for FY25 focusing on capacity expansions and backward integration supporting future growth.
→Debt levels may remain stable or slightly higher due to ongoing capex, with cost of debt around 7.5%–8%, expected to remain stable.
→Tax rate expected around 12-16% for FY25 and FY26.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→There is no explicit mention of any new fundraising through debt or equity in the provided transcript.
→The company is undertaking significant capex of INR 1,500-1,800 crores in FY25 and expects similar or upward capex in FY26, primarily funded through ongoing resources.
→Chetan Gandhi mentioned that debt levels are not expected to reduce on an absolute basis due to ongoing capex, but working capital optimization efforts are underway.
→The management did not indicate any plans for new equity fundraising.
→Cost of debt is currently around 7.5%-8% and expected to remain similar next year, indicating reliance on existing debt facilities.
→Overall, the company seems to be managing expansion via internal accruals and existing debt rather than new external fundraising at this time.

Order book

- MMA long-term contract: INR 900 crores revenue in FY'24, expected to ramp up to INR 1,500 crores in FY'25 (50%-60% YoY increase). - Deepak Fertilizers contract: INR 8,000 crore contract over 20 years, implying about INR 400 crores annual revenue. - Nitro Toluene and downstream volumes are partially tied up with customers, with commissioning expected by Q2 FY25. - Ongoing projects such as Acid Phase-2, Ethylation expansion, Nitro Toluene expansion, specialty chemicals blocks are scheduled for FY25 commissioning. - Chloro Toluene project expected to start initial phase by FY26. - Sustained recovery in discretionary segments and emerging revival in non-discretionary portfolio expected to drive order volumes and backlog ramp-up. - Volume growth expected post-FY25 with expansion in capacities and new product line ramp-up. Overall, order backlog and contracts indicate strong revenue visibility with gradual ramp-ups over FY25 and beyond.

Capex plans

Yes

→FY'24 capex was over INR 1,280 crore on project expansions.
→Planned capex for FY'25 is INR 1,500-1,800 crore.
→Major ongoing expansions include Acid Phase-2 Capacity Expansion, Specialty Chemicals Blocks, Ethylation, Nitro Toluene capacities, and asset upgradation.
→Phase-1 of the Chloro Toluene project is expected to commence by FY'26.
→FY'26 capex likely to exceed INR 1,000 crore but exact numbers are yet to be finalized.
→Over the next two years, total planned investment is approximately INR 3,000-3,500 crore.
→More than 50% of FY'26 capex will be allocated to the new site expansion at Jhagadia, including multipurpose and Chloro Toluene plants.
→Capex is largely productive, focused on revenue growth and backward integration, with minimal maintenance capex.
→Growth initiatives aimed at strengthening the company’s position in the global chemical value chain.

How does Aarti Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Aarti Industries Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Aarti Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio